Nanoparticle delivered vascular disrupting agents (VDAs): Use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1683-1694

  Shenoi, Mithun M ^a   Iltis, Isabelle ^b   Choi, Jeunghwan ^a   Koonce, Nathan A ^d   Metzger, Gregory J ^b   Griffin, Robert J ^d   Bischof, John C ^a,c  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

cancer; CYT 6091; DCE MRI; gold nanoparticles; thermal therapy; TNF alpha; vascular disrupting agent

Indexed keywords

COPOLYMER; DEXTRAN; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; MYELOPEROXIDASE; PEPTIDE; PHOSPHATIDYLCHOLINE; POLYLACTIC ACID; POVIDONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; GOLD; METAL NANOPARTICLE; NANOCONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRYOTHERAPY; HYPERTHERMIC THERAPY; IMMUNOREGULATION; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKINFOLD; TEMPERATURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG SCREENING; HUMAN; NUDE MOUSE; PROSTATIC NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GOLD; HUMANS; HYPERTHERMIA, INDUCED; MALE; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOCONJUGATES; PROSTATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877311249     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300505w     Document Type: Article

References (59)

1. Chang, S. S. Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure J. Urol. 2006, 176 (6 Part 2) S57-60 discussion S55-6
2. D'Amico, A. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective - identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy BJU Int. 2007, 99 (Suppl. 1) 13-6 discussion 17-8
3. Horsman, M. R.; Bohn, A. B.; Busk, M. Vascular targeting therapy: potential benefit depends on tumor and host related effects Exp. Oncol. 2010, 32 (3) 143-8
4. Horsman, M. R.; Murata, R. Combination of vascular targeting agents with thermal or radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 2002, 54 (5) 1518-23
5. Chao, B. H.; He, X.; Bischof, J. C. Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer Cryobiology 2004, 49 (1) 10-27
6. Balkwill, F. Tumour necrosis factor and cancer Nat. Rev. Cancer 2009, 9 (5) 361-71
7. Rustin, G. J.; Galbraith, S. M.; Anderson, H.; Stratford, M.; Folkes, L. K.; Sena, L.; Gumbrell, L.; Price, P. M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J. Clin. Oncol. 2003, 21 (15) 2815-22
8. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W. P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J. S.; McCrae, K. R.; Remick, S. C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res. 2002, 62 (12) 3408-16
9. Cooney, M. M.; Radivoyevitch, T.; Dowlati, A.; Overmoyer, B.; Levitan, N.; Robertson, K.; Levine, S. L.; DeCaro, K.; Buchter, C.; Taylor, A.; Stambler, B. S.; Remick, S. C. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer Clin. Cancer Res. 2004, 10 (1 Part 1) 96-100
10. Rustin, G. J.; Bradley, C.; Galbraith, S.; Stratford, M.; Loadman, P.; Waller, S.; Bellenger, K.; Gumbrell, L.; Folkes, L.; Halbert, G. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study Br. J. Cancer 2003, 88 (8) 1160-7
11. Lejeune, F.; Lienard, D.; Eggermont, A. Regional Administration of Recombinant Tumour Necrosis Factor-alpha in Cancer, with Special Reference to Melanoma BioDrugs 1998, 9 (3) 211-8
12. Grunhagen, D. J.; de Wilt, J. H.; van Geel, A. N.; Verhoef, C.; Eggermont, A. M. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities Recent Results Cancer Res. 2009, 179, 257-70
13. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R., Jr.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine Clin. Cancer Res. 2010, 16 (24) 6139-49
14. Goel, R.; Swanlund, D.; Coad, J.; Paciotti, G. F.; Bischof, J. C. TNF-{alpha}-based accentuation in cryoinjury-dose, delivery, and response Mol. Cancer Ther. 2007, 6 (7) 2039-47
15. Jiang, J.; Goel, R.; Schmechel, S.; Vercellotti, G.; Forster, C.; Bischof, J. Pre-Conditioning Cryosurgery: Cellular and Molecular Mechanisms and Dynamics of TNF-alpha Enhanced Cryotherapy in an in vivo Prostate Cancer Model System Cryobiology 2010, 61 (3) 280-8
16. Visaria, R. K.; Griffin, R. J.; Williams, B. W.; Ebbini, E. S.; Paciotti, G. F.; Song, C. W.; Bischof, J. C. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-{alpha} delivery Mol. Cancer Ther. 2006, 5 (4) 1014-1020
17. Farma, J. M.; Puhlmann, M.; Soriano, P. A.; Cox, D.; Paciotti, G. F.; Tamarkin, L.; Alexander, H. R. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor Int. J. Cancer 2007, 120 (11) 2474-80
18. Bierhaus, A.; Zhang, Y.; Deng, Y.; Mackman, N.; Quehenberger, P.; Haase, M.; Luther, T.; Muller, M.; Bohrer, H.; Greten, J. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor J. Biol. Chem. 1995, 270 (44) 26419-32
19. Prinzen, F. W.; Bassingthwaighte, J. B. Blood flow distributions by microsphere deposition methods Cardiovasc. Res. 2000, 45 (1) 13-21
20. Rosset, A.; Spadola, L.; Ratib, O. OsiriX: an open-source software for navigating in multidimensional DICOM images J. Digital Imaging 2004, 17 (3) 205-16
21. Daldrup, H. E.; Shames, D. M.; Husseini, W.; Wendland, M. F.; Okuhata, Y.; Brasch, R. C. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries Magn. Reson. Med. 1998, 40 (4) 537-43
22. Deoni, S. C.; Peters, T. M.; Rutt, B. K. High-resolution T1 and T2 mapping of the brain in a clinically acceptable time with DESPOT1 and DESPOT2 Magn Reson Med. 2005, 53 (1) 237-41
23. Jiang, J.; Goel, R.; Iftekhar, M. A.; Visaria, R.; Belcher, J. D.; Vercellotti, G. M.; Bischof, J. C. Tumor necrosis factor-{alpha}-induced accentuation in cryoinjury: mechanisms in vitro and in vivo Mol Cancer Ther. 2008, 7 (8) 2547-2555
24. Jiang, J.; Bischof, J. Effect of timing, dose and interstitial versus nanoparticle delivery of tumor necrosis factor alpha in combinatorial adjuvant cryosurgery treatment of ELT-3 uterine fibroid tumor Cryo Lett. 2010, 31 (1) 50-62
25. Breitbach, C. J.; De Silva, N. S.; Falls, T. J.; Aladl, U.; Evgin, L.; Paterson, J.; Sun, Y. Y.; Roy, D. G.; Rintoul, J. L.; Daneshmand, M.; Parato, K.; Stanford, M. M.; Lichty, B. D.; Fenster, A.; Kirn, D.; Atkins, H.; Bell, J. C. Targeting tumor vasculature with an oncolytic virus Mol. Ther. 2011, 19 (5) 886-94
26. R Development Core Team. R: A language and environment for statistical computing; R Foundation for Statistical Computing: Vienna, Austria, 2011; ISBN 3-900051-07-0, URI http://www.R-project.org/.
27. Visaria, R.; Bischof, J. C.; Loren, M.; Williams, B.; Ebbini, E.; Paciotti, G.; Griffin, R. Nanotherapeutics for enhancing thermal therapy of cancer Int. J. Hyperthermia 2007, 23 (6) 501-11
28. Spear, M. A.; LoRusso, P.; Mita, A.; Mita, M. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic Curr. Drug Targets 2011, 12 (14) 2009-15
29. Heidel, J. D.; Davis, M. E. Clinical developments in nanotechnology for cancer therapy Pharm. Res. 2011, 28 (2) 187-99
30. Shenoi, M. M.; Shah, N. B.; Griffin, R. J.; Vercellotti, G. M.; Bischof, J. C. Nanoparticle preconditioning for enhanced thermal therapies in cancer Nanomedicine 2011, 6 (3) 545-563
31. Poon, R. T. P.; Borys, N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer Fut. Oncol. 2011, 7 (8) 937-945
32. Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 2009, 9 (5) 1909-15
33. Shah, N. B.; Vercellotti, G. M.; White, J. G.; Fegan, A.; Wagner, C. R.; Bischof, J. C. Blood-Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties Mol. Pharmaceutics 2012, 9 (8) 2146-55
34. Ferrero, E.; Zocchi, M. R.; Magni, E.; Panzeri, M. C.; Curnis, F.; Rugarli, C.; Ferrero, M. E.; Corti, A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability Am. J. Physiol. 2001, 281 (4) C1173-9
35. Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents Cancer Treat. Rev. 2011, 37 (1) 63-74
36. Nathan, P.; Zweifel, M.; Padhani, A. R.; Koh, D. M.; Ng, M.; Collins, D. J.; Harris, A.; Carden, C.; Smythe, J.; Fisher, N.; Taylor, N. J.; Stirling, J. J.; Lu, S. P.; Leach, M. O.; Rustin, G. J.; Judson, I. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer Clin. Cancer Res. 2012, 18 (12) 3428-39
37. Mukherjee, P.; Bhattacharya, R.; Wang, P.; Wang, L.; Basu, S.; Nagy, J. A.; Atala, A.; Mukhopadhyay, D.; Soker, S. Antiangiogenic properties of gold nanoparticles Clin. Cancer Res. 2005, 11 (9) 3530-4
38. Hoffmann, N. E.; Bischof, J. C. Cryosurgery of normal and tumor tissue in the dorsal skin flap chamber: Part I-thermal response J. Biomech. Eng. 2001, 123 (4) 301-9
39. Hoffmann, N. E.; Bischof, J. C. Cryosurgery of normal and tumor tissue in the dorsal skin flap chamber: Part II-injury response J. Biomech. Eng. 2001, 123 (4) 310-6
40. Bhowmick, S.; Hoffmann, N. E.; Bischof, J. C. Thermal therapy of prostate tumor tissue in the dorsal skin flap chamber Microvasc. Res. 2002, 64 (1) 170-3
41. Bhowmick, S.; Coad, J. E.; Swanlund, D. J.; Bischof, J. C. In vitro thermal therapy of AT-1 Dunning prostate tumours Int. J. Hyperthermia 2004, 20 (1) 73-92
42. Bischof, J. C.; Smith, D.; Pazhayannur, P. V.; Manivel, C.; Hulbert, J.; Roberts, K. P. Cryosurgery of dunning AT-1 rat prostate tumor: thermal, biophysical, and viability response at the cellular and tissue level Cryobiology 1997, 34 (1) 42-69
43. Fukumura, D.; Salehi, H. A.; Witwer, B.; Tuma, R. F.; Melder, R. J.; Jain, R. K. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain Cancer Res. 1995, 55 (21) 4824-9
44. Mileski, W. J.; Raymond, J. F.; Winn, R. K.; Harlan, J. M.; Rice, C. L. Inhibition of leukocyte adherence and aggregation for treatment of severe cold injury in rabbits J. Appl. Physiol. 1993, 74 (3) 1432-6
45. Johansson, A.; Hamzah, J.; Payne, C. J.; Ganss, R. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (20) 7841-6
46. Thamm, D. H.; Kurzman, I. D.; Clark, M. A.; Ehrhart, E. J., 3rd; Kraft, S. L.; Gustafson, D. L.; Vail, D. M. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation Clin. Cancer Res. 2010, 16 (5) 1498-508
47. Tsunoda, S.; Ishikawa, T.; Yamamoto, Y.; Kamada, H.; Koizumi, K.; Matsui, J.; Tsutsumi, Y.; Hirano, T.; Mayumi, T. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent J. Pharmacol. Exp. Ther. 1999, 290 (1) 368-72
48. Tsutsumi, Y.; Tsunoda, S.; Kamada, H.; Kihira, T.; Nakagawa, S.; Kaneda, Y.; Kanamori, T.; Mayumi, T. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency Br. J. Cancer 1996, 74 (7) 1090-5
49. Yamamoto, Y.; Tsutsumi, Y.; Yoshioka, Y.; Nishibata, T.; Kobayashi, K.; Okamoto, T.; Mukai, Y.; Shimizu, T.; Nakagawa, S.; Nagata, S.; Mayumi, T. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity Nat. Biotechnol. 2003, 21 (5) 546-52
50. Yoshioka, Y.; Tsutsumi, Y.; Ikemizu, S.; Yamamoto, Y.; Shibata, H.; Nishibata, T.; Mukai, Y.; Okamoto, T.; Taniai, M.; Kawamura, M.; Abe, Y.; Nakagawa, S.; Nagata, S.; Yamagata, Y.; Mayumi, T. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency Biochem. Biophys. Res. Commun. 2004, 315 (4) 808-14
51. Kamada, H.; Tsutsumi, Y.; Yamamoto, Y.; Kihira, T.; Kaneda, Y.; Mu, Y.; Kodaira, H.; Tsunoda, S. I.; Nakagawa, S.; Mayumi, T. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice Cancer Res. 2000, 60 (22) 6416-20
52. Kaneda, Y.; Yamamoto, Y.; Kamada, H.; Tsunoda, S.; Tsutsumi, Y.; Hirano, T.; Mayumi, T. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice Cancer Res. 1998, 58 (2) 290-5
53. Tabata, Y.; Noda, Y.; Matsui, Y.; Ikada, Y. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination J. Controlled Release 1999, 59 (2) 187-96
54. Corti, A.; Ponzoni, M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs Ann. N.Y. Acad. Sci. 2004, 1028, 104-12
55. Borsi, L.; Balza, E.; Carnemolla, B.; Sassi, F.; Castellani, P.; Berndt, A.; Kosmehl, H.; Biro, A.; Siri, A.; Orecchia, P.; Grassi, J.; Neri, D.; Zardi, L. Selective targeted delivery of TNFalpha to tumor blood vessels Blood 2003, 102 (13) 4384-92
56. ten Hagen, T. L.; Seynhaeve, A. L.; van Tiel, S. T.; Ruiter, D. J.; Eggermont, A. M. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats Int. J. Cancer 2002, 97 (1) 115-20
57. Li, Y. P.; Pei, Y. Y.; Zhou, Z. H.; Zhang, X. Y.; Gu, Z. H.; Ding, J.; Zhou, J. J.; Gao, X. J.; Zhu, J. H. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects Biol. Pharm. Bull. 2001, 24 (6) 662-5
58. Arora, A.; Su, G.; Mathiowitz, E.; Reineke, J.; Chang, A. E.; Sabel, M. S. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity J. Surg. Oncol. 2006, 94 (5) 403-12
59. Sabel, M. S.; Skitzki, J.; Stoolman, L.; Egilmez, N. K.; Mathiowitz, E.; Bailey, N.; Chang, W. J.; Chang, A. E. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity Ann. Surg. Oncol. 2004, 11 (2) 147-56